News

Tinley’s Provides Corporate Update and Announces Results of Its 2024 Annual and Special Meeting of Shareholders

Toronto, Ontario and Los Angeles, California--(Newsfile Corp. - December 9, 2024) - The Tinley Beverage Company Inc. (CSE: TNY) (OTCQB:…

1 year ago

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in…

1 year ago

Prezent Sets New Milestones with Record Revenue in 2024, Unveils AI-Driven Vision for Enterprise Communication, and Secures Backing from New Investors True Global Ventures and Zoom Ventures to Accelerate Hyper-Growth in 2025

LOS ALTOS, Calif., Dec. 9, 2024 /PRNewswire/ -- Prezent, the Enterprise Business Storytelling Platform, announced today multiple key milestones achieved in…

1 year ago

Bioz Stars Awards 2024: Recognizing the World’s Top Suppliers in Scientific Innovation

PALO ALTO, CA / ACCESSWIRE / December 9, 2024 / Bioz, Inc, a leader in AI-powered solutions for scientific research,…

1 year ago

CeraVx B.V. Emerges from Stealth Acquires Micro Needle Technology from MLT Appoints Management and Supervisory Board

CeraVx BV successful bid to acquire key micro needle technology from MLTManagement team:Dr. Jan Groen as CEO,Dinja Oosterhof , PhD…

1 year ago

BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment

VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience…

1 year ago

Hemogenyx Pharmaceuticals PLC Announces Site Initiation Visit Completed

Hemogenyx Pharmaceuticals Successfully Completes the Site Initiation Visit of the First Clinical Site for Phase I Clinical Trial of HG-CT-1…

1 year ago

Scryb Launches New AI Governance Technology Business Unit, ‘Raidian’

Toronto, Ontario--(Newsfile Corp. - December 8, 2024) - Scryb Inc.  (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) ("Scryb'' or the "Company"), is pleased…

1 year ago

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and…

1 year ago